Difficulty: Intermediate | Prerequisites: Part 1 of these notes (Genetics and Environmental Factors), basic neuroanatomy (ventricles, cortices, neurotransmitters)
This is the second half of the schizophrenia material. Part 1 covered genetic and environmental risk factors; this set picks up with what schizophrenia looks like in the brain, how it presents clinically, and how it is treated. You need all three symptom categories (positive, negative, cognitive) cold for the exam, and you should be able to link each one to its underlying neurobiology. The treatment section distinguishes typical from atypical antipsychotics and introduces emerging approaches. If you have not reviewed dopamine pathways and basic pharmacology, do that before reading further.
Schizophrenia involves measurable brain changes (enlarged ventricles, grey matter loss), and its symptoms fall into three categories: positive (hallucinations, delusions), negative (withdrawal, flat affect), and cognitive (memory and attention deficits). Typical antipsychotics target positive symptoms via dopamine blockade; atypical antipsychotics offer a broader profile. Newer research is exploring cannabinoid, anti-inflammatory, and nutritional approaches.
Enlarged lateral ventricles
The fluid-filled cavities in the brain are larger than normal in many schizophrenia patients, indicating a loss of surrounding brain tissue. Think of it as the ventricles expanding to fill space where brain matter has been lost.
Grey matter
Brain tissue composed mainly of neuronal cell bodies, found in the cortex and deep brain structures. In simple terms, it is the "processing" tissue of the brain, as opposed to white matter (the "wiring").
Positive symptoms
Symptoms that represent an excess or distortion of normal function, such as hallucinations, delusions, and thought disorder. They are called "positive" because they add something to the person's experience that is not normally present, not because they are good.
Negative symptoms
Symptoms reflecting a reduction or absence of normal function: diminished emotional expression (flat affect), avolition (lack of motivation), anhedonia (inability to feel pleasure), and social withdrawal. Think of them as things that have been taken away from the person's normal functioning.
Avolition
A persistent lack of motivation or initiative. In simple terms, the person struggles to start or follow through on goal-directed activity, even basic daily tasks.
Anhedonia
The inability to experience pleasure from activities that would normally be enjoyable. This is shared with major depressive disorder and is one of the most disabling negative symptoms.
Cognitive symptoms
Deficits in attention, working memory, and executive functions (planning, problem-solving, abstract thinking). These are often present before the first psychotic episode and tend to persist even when other symptoms improve with medication.
Typical antipsychotics (first-generation antipsychotics)
Older medications such as chlorpromazine that primarily block dopamine D2 receptors. Effective for positive symptoms but largely ineffective for negative and cognitive symptoms. Think of them as a blunt tool: they turn down dopamine across the board.
Atypical antipsychotics (second-generation antipsychotics)
Newer medications such as aripiprazole that modulate dopamine activity more selectively. Aripiprazole, for example, acts as a partial agonist at dopamine receptors, meaning it can both increase and decrease dopamine signalling depending on the brain region. This broader mechanism helps with both positive and negative symptoms.
Partial agonist
A substance that binds to a receptor and activates it, but with less than full efficacy compared to a full agonist. In simple terms, it turns the signal partly on rather than all the way on, which allows it to stabilise activity in both overactive and underactive circuits.
Neurodevelopmental hypothesis
The idea that schizophrenia originates from disruptions in brain development before birth, rather than from damage occurring in adulthood. Supporting evidence includes the DISC1 mouse studies and the association between prenatal complications and later diagnosis.
Enlarged ventricles
MRI and CT scans consistently show enlarged lateral ventricles in schizophrenia patients
This indicates loss of surrounding brain tissue, not an excess of cerebrospinal fluid production
Present in many patients at first episode, suggesting it is not solely a consequence of medication or illness duration
Grey matter reduction
Greater rate of grey matter loss in the frontal and temporal cortices compared to healthy controls
Frontal cortex involvement helps explain executive function deficits (planning, decision-making)
Temporal cortex involvement is relevant to auditory hallucinations and language disturbance
Prenatal disturbances in brain development may be the root cause of schizophrenia
Evidence from animal models: disrupting the DISC1 gene in mice during fetal development produces schizophrenia-like symptoms in adulthood
This hypothesis explains why schizophrenia often emerges in late adolescence or early adulthood, a period when the brain undergoes significant synaptic pruning and the consequences of earlier developmental errors become apparent
Positive symptoms
Hallucinations (most commonly auditory, e.g. hearing voices)
Delusions (false beliefs, e.g. persecution, grandeur)
Thought disorder (disorganised speech, loose associations)
Linked to overactivity in dopamine pathways, specifically the mesolimbic pathway
Negative symptoms
Diminished emotional expression (flat or blunted affect)
Avolition (lack of initiative or motivation)
Anhedonia (inability to experience pleasure)
Social withdrawal
Harder to treat than positive symptoms; often more disabling in the long term
Linked to underactivity in dopamine pathways, specifically the mesocortical pathway
Cognitive symptoms
Difficulties with attention, working memory, and executive functions (problem-solving, abstract thinking)
Often present before the first psychotic episode (prodromal phase)
Tend to persist even when positive symptoms are controlled with medication
Among the strongest predictors of functional outcome (ability to work, live independently)
Typical antipsychotics (first-generation)
Example: chlorpromazine
Mechanism: block dopamine D2 receptors, reducing dopamine transmission
Effective for positive symptoms (hallucinations, delusions)
Limited effect on negative and cognitive symptoms
Side effects include extrapyramidal symptoms (movement disorders), tardive dyskinesia (involuntary movements with long-term use), and sedation
Atypical antipsychotics (second-generation)
Example: aripiprazole
Mechanism: aripiprazole acts as a partial agonist at dopamine receptors, modulating dopamine activity up or down depending on the brain region
This dual action helps address both positive and negative symptoms
Generally fewer extrapyramidal side effects than typical antipsychotics, though metabolic side effects (weight gain, diabetes risk) can be a concern with some drugs in this class
Novel approaches (emerging research)
Cannabinoid agonists: cannabidiol (CBD) and other compounds interacting with the endocannabinoid system are being explored for antipsychotic properties
Anti-inflammatory treatments: given evidence that inflammation may play a role in schizophrenia, anti-inflammatory drugs are under investigation
Nutritional supplements: prenatal choline supplementation may reduce the risk of schizophrenia developing later in life
Understanding the three symptom categories matters for clinical work. Positive symptoms are what most people picture when they think of schizophrenia, but negative and cognitive symptoms are often more debilitating in daily life and harder to treat. Rehabilitation programmes focus heavily on cognitive remediation (structured exercises to improve attention and memory) precisely because cognitive symptoms predict whether someone can hold a job or live independently, regardless of whether their hallucinations are controlled.
"Positive symptoms are the 'good' symptoms." "Positive" here means additive (something added to normal experience), not beneficial. Hallucinations and delusions are distressing and potentially dangerous.
"Antipsychotics cure schizophrenia." They manage symptoms, particularly positive ones. Most patients require lifelong treatment, and negative and cognitive symptoms often persist despite medication.
"Enlarged ventricles are caused by antipsychotic medication." Ventricular enlargement is present in many first-episode patients who have never been medicated, indicating it is part of the disease process itself.
"Schizophrenia always involves violent behaviour." This is a pervasive stigma. The vast majority of people with schizophrenia are not violent. They are far more likely to be victims of violence than perpetrators.
⚠️ Know all three symptom categories and be able to give examples of each. This is nearly guaranteed on the exam.
⚠️ Be able to link positive symptoms to mesolimbic dopamine overactivity and negative symptoms to mesocortical dopamine underactivity.
⚠️ Understand the difference between typical and atypical antipsychotics: mechanism, which symptoms they target, and their side-effect profiles.
⚠️ Aripiprazole as a partial agonist is a common exam item. Know what "partial agonist" means and why it offers a more balanced approach.
⚠️ The neurodevelopmental hypothesis and its supporting evidence (DISC1 mouse studies, prenatal complications) is a frequent short-answer topic.
⚠️ Cognitive symptoms as the strongest predictor of functional outcome is a detail examiners like to test.
True or False: "Positive symptoms" in schizophrenia means symptoms that are beneficial to the patient.
Fill in the blank: Typical antipsychotics primarily block dopamine _______ receptors.
True or False: Cognitive symptoms of schizophrenia typically resolve once positive symptoms are treated.
Fill in the blank: Aripiprazole is classified as a partial _______ at dopamine receptors.
True or False: Enlarged lateral ventricles in schizophrenia are thought to indicate loss of brain tissue.
Answers: 1. False ("positive" means additive, i.e. something added to normal experience). 2. D2. 3. False (cognitive symptoms tend to persist even when positive symptoms improve). 4. Agonist. 5. True.
Q: Compare and contrast positive, negative, and cognitive symptoms of schizophrenia. Give one example of each.
A: Positive symptoms are additions to normal experience (e.g. auditory hallucinations). Negative symptoms are reductions in normal functioning (e.g. avolition, the inability to initiate goal-directed activity). Cognitive symptoms are deficits in mental processes (e.g. impaired working memory). Positive symptoms are linked to mesolimbic dopamine overactivity; negative symptoms to mesocortical dopamine underactivity; cognitive symptoms involve frontal lobe dysfunction and are the strongest predictors of long-term functional outcome.
Q: Explain how atypical antipsychotics differ from typical antipsychotics in mechanism and clinical effect.
A: Typical antipsychotics (e.g. chlorpromazine) block dopamine D2 receptors broadly, which effectively reduces positive symptoms but does little for negative or cognitive symptoms and carries a risk of extrapyramidal side effects. Atypical antipsychotics (e.g. aripiprazole) modulate dopamine more selectively. Aripiprazole acts as a partial agonist, meaning it can increase dopamine signalling in underactive regions (helping negative symptoms) while reducing it in overactive regions (helping positive symptoms), with generally fewer movement-related side effects.
Q: What brain structure abnormalities are associated with schizophrenia, and what do they suggest about the disorder?
A: Patients commonly show enlarged lateral ventricles (indicating loss of brain tissue) and reduced grey matter in the frontal and temporal cortices. These findings are present in some first-episode patients, supporting the neurodevelopmental hypothesis that schizophrenia involves disrupted brain development rather than degeneration that begins with symptom onset.
Q: What is the neurodevelopmental hypothesis of schizophrenia? Cite one piece of supporting evidence.
A: The neurodevelopmental hypothesis proposes that schizophrenia originates from disruptions to brain development during the prenatal period. Supporting evidence includes mouse studies in which disrupting the DISC1 gene during fetal development led to schizophrenia-like symptoms in adulthood, demonstrating that early developmental interference can produce the disorder's hallmarks later in life.
Q: Name two novel treatment approaches being researched for schizophrenia and briefly explain the rationale for each.
A: (1) Cannabinoid agonists, particularly CBD, are being explored because compounds acting on the endocannabinoid system may have antipsychotic properties. (2) Anti-inflammatory treatments are under investigation because emerging evidence suggests inflammation may contribute to schizophrenia's pathology, so reducing neuroinflammation could complement existing pharmacological approaches.
The dopamine pathways covered here (mesolimbic, mesocortical) also appear in topics on substance use disorders and reward processing. The distinction between typical and atypical antipsychotics connects to broader psychopharmacology content. Negative symptoms, especially anhedonia, overlap significantly with major depressive disorder, which is worth noting when studying comorbidity. The neurodevelopmental hypothesis ties back to Part 1 of these notes (DISC1, obstetric complications, prenatal environment).
schizophrenia neurobiology, enlarged ventricles schizophrenia, grey matter loss, frontal cortex temporal cortex, positive symptoms negative symptoms cognitive symptoms, hallucinations delusions, avolition anhedonia flat affect, dopamine hypothesis, mesolimbic mesocortical pathway, typical antipsychotics, first-generation antipsychotics, chlorpromazine, atypical antipsychotics, second-generation antipsychotics, aripiprazole, partial agonist, neurodevelopmental hypothesis, DISC1 mouse model, cannabidiol antipsychotic, anti-inflammatory schizophrenia, choline supplementation, cognitive remediation, abnormal psychology, University of Florida